2-(4-(4-Ethoxybenzoyl)piperidin-1-yl)acetic acid → 2-(4-(4-Ethoxybenzoyl)piperidin-1-yl)-N-((4-oxo-4,5,7,8-tetrahydro-3H-pyrano[4,3-d]pyrimidin-2-yl)methyl)acetamide

Participants

Reaction Steps

The title compound (150 mg) was prepared following the general procedure of Example 1 from 2-aminomethyl-3,5,7,8-tetrahydro-pyrano[4,3-d]pyrimidin-4-one (300 mg, 1.66 mmol) and 2-(4-(4-ethoxybenzoyl)piperidin-1-yl)acetic acid (603 mg, 1.66 mmol). 1H NMR (400 MHz, CDC3) δ 10.67 (s, 1H), 8.07 (t, J=6.0 Hz, 1H), 7.92 (d, J=9.0 Hz, 2H), 6.94 (t, J=9.0 Hz, 2H), 4.56 (s, 2H), 4.37 (d, J=6.0 Hz, 2H), 4.10 (q, J=7.0 Hz, 2H), 3.95 (t, J=5.5 Hz, 2H), 3.20-3.29 (m, 1H), 2.91-3.00 (m, 2H), 2.66-2.72 (m, 2H), 2.30-2.40 (m, 2H), 1.80-1.90 (m, 4H), 1.45 (t, J=7.0 Hz, 3H). HRMS calculated for C24H30N4O5 455.2294. found (ESI, [M+H]+), 455.2308. MS m/z 455.2 (M+1), retention time=2.70 min.

Provenance & Evidence